A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
KRAS G12C

About this trial
This is an interventional treatment trial for KRAS G12C
Eligibility Criteria
Inclusion Criteria:
- Men or women ≥18 years old
- Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation
- Adequate organ function
- Measurable disease per RECIST 1.1 criteria.
Exclusion Criteria:
- Significant concomitant diseases
- Active brain metastases
- Previous treatment with KRAS G12C inhibitor.
Sites / Locations
- Guangdong Provincial People's HospitalRecruiting
Arms of the Study
Arm 1
Experimental
GFH925
Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design. Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently. Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy. Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.